PLoS Biol 16(5)
By doing so, we aspire to generate insights that can guide the development of precision-targeted therapies, aligning with the existing clinical treatment strategy
Additionally, a 2017 review by Lo et al
There is a particular need for human studies focused on the following: (i) validation of airway and systemic GSH/GSSG redox balance as a biomarker of asthma susceptibility, (ii) the natural history of GSH/GSSG redox balance in asthma across the lifespan, (iii) the specific role of GSH/GSSG redox balance in clinical manifestations of the disorder, including asthma severity and the response to secondary insults, (iv) the utility of GSH/GSSG redox balance as a predictor and indictor of asthma treatment responsiveness, and (v) therapeutic approaches to restore the GSH/GSSG redox balance in asthma and modify the course of the disorder
Histone acetyl transferase (HATs) family, which catalyzes the transfer of the acetyl group from acetyl-CoA to histones, including P300/CBP, MOF, GCN5 and TIP60 are also reported catalyzes the transfer of lactate groups from lactate-CoA to histones in different disease and disease states [16, 88, 165, 181, 182]
Future predictions Likely scenarios: More peptides will get FDA approval: Clinical trials ongoing for many peptides If approved, they shift to prescription-only Continued gray area for research peptides: Unlikely FDA will ban possession More likely to restrict sales/marketing Gray area probably persists Increased quality control: Pressure on research peptide industry to ensure quality Third-party testing becoming standard More telehealth access: Legal prescription access becoming easier Online platforms expanding Staying legal: best practices If using research peptides Buy from reputable sources with third-party testing Don't import large quantities (personal amounts only) Don't resell or distribute (keeps you in personal use category) Understand it's gray area (legal risk is low but not zero) Keep discrete (don't advertise use) Use our peptide calculator to determine personal use amounts
